Douglas Ingram

2017

In 2017, Douglas Ingram earned a total compensation of $56.9M as President and Chief Executive Officer at Sarepta Therapeutics.

Compensation breakdown

Non-Equity Incentive Plan$420,875
Option Awards$44,484,000
Salary$337,500
Stock Awards$11,607,750
Other$16,116
Total$56,866,241

Ingram received $44.5M in option awards, accounting for 78.23% of the total pay in 2017.

Ingram also received $420.9K in non-equity incentive plan, $337.5K in salary, $11.6M in stock awards and $16.1K in other compensation.

Rankings

In 2017, Douglas Ingram's compensation ranked 20th out of 13,928 executive pay records tracked by us. In other words, Ingram earned more than 99.9% of all executives tracked by us in 2017.

ClassificationRankingPercentile
All
20
out of 13,928
100th
Manufacturing
Division
4
out of 5,498
100th
Chemicals And Allied Products
Major group
1
out of 1,943
100th
Drugs
Industry group
1
out of 1,610
100th
Pharmaceutical Preparations
Industry
1
out of 1,236
100th
Source: SEC filing on April 26, 2018.

Ingram's colleagues

We found six more compensation records of executives who worked with Douglas Ingram at Sarepta Therapeutics in 2017.

2017

Edward Kaye

Sarepta Therapeutics

Chief Executive Officer

2017

Guriqbal Basi

Sarepta Therapeutics

Chief Scientific Officer

2017

Alexander Cumbo

Sarepta Therapeutics

Senior Vice President, Chief Commercial Officer

2017

Sandesh Mahatme

Sarepta Therapeutics

Chief Financial Officer

2017

David Howton

Sarepta Therapeutics

General Counsel

2017

Catherine Stehman-Breen

Sarepta Therapeutics

Chief Medical Officer

News

In-depth

You may also like